Quick Facts

• Chronic Arthritis: Employed in the management of moderate-to-severe Rheumatoid Arthritis in adult patients.
• Skin Condition: Assists in addressing the manifestations of chronic Plaque Psoriasis.
• Bowel Health: Contributes to the clinical management of moderately active Ulcerative Colitis.

Limagal is a prescription medication utilized in therapeutic regimens for multiple conditions characterized by underlying inflammation. Its primary role involves helping to manage the signs and symptoms associated with moderate-to-severe Rheumatoid Arthritis (RA) in adult populations. For this condition, it may be integrated into a comprehensive treatment plan to support joint comfort and function.

Limagal also serves as a component of the care strategy for individuals presenting with chronic Plaque Psoriasis. Its application in this domain is intended to help diminish the severity and extent of related skin manifestations.

Furthermore, this medication is indicated for the treatment of moderately active Ulcerative Colitis. In this context, the objective is to assist in achieving and maintaining clinical response and supporting symptom reduction. All therapeutic uses are based on approved indications, and this medication should only be used as directed by a healthcare professional.

Regulatory References

1. NIH MedlinePlus therapeutic overview

Eligibility Map: Who can and cannot use Limagal — Official Regulatory Information

The eligibility profile for Limagal is defined by a framework of absolute prohibitions and population-specific restrictions documented in official regulatory sources.

Official Eligibility Statements

• Contraindicated: Limagal is officially contraindicated in cases of known hypersensitivity to the drug's components.
• Use Not Established: Use is not established for any pediatric age group (under 18 years).
• Not Recommended: Use is generally not recommended for patients with advanced organ dysfunction or during physiological states of pregnancy and lactation.

Eligibility Classification Summary

Regulatory documents define who can and cannot use Limagal by strictly establishing Contraindications that prohibit use and by identifying Restricted-Use groups due to insufficient clinical data or established risks. This framework ensures that the drug is only administered to populations where its safety and efficacy have been confirmed, or where risks are managed under specific conditional use statements.

The official regulatory profile for Limagal is defined by two primary interaction patterns: chelation and additive systemic load.

The magnesium cation in Limagal can bind to several oral medications in the digestive tract, causing a pharmacokinetic interaction that results in reduced absorption and decreased bioavailability of the co-administered drug. This reduction in exposure is explicitly documented for drug classes including:

• Quinolone Antibiotics (e.g., Ciprofloxacin, Levofloxacin)
• Tetracycline Antibiotics (e.g., Doxycycline, Minocycline)
• Oral Bisphosphonates (e.g., Alendronate)

To address this chelation risk, regulatory labeling requires mandatory administration timing separation. For antibiotics, this separation must be 2 to 4 hours before or 4 to 6 hours after the magnesium product. Bisphosphonates must be separated by at least 2 hours.

A separate pharmacodynamic interaction involves the risk of Hypermagnesemia (magnesium toxicity). This risk is associated with an additive systemic mineral load when Limagal is combined with other magnesium-containing preparations (such as certain laxatives or antacids). Regulatory notes classify this as a significant risk for specific populations, particularly those with Compromised Renal Function and Elderly Patients, due to their reduced ability to clear the mineral. Co-administration with High-dose Zinc Supplements is also noted to potentially alter magnesium regulation.

Limagal is a formulation containing magnesium lactate, which dissociates to release the magnesium divalent cation Mg^2+. Following absorption from the gastrointestinal tract, the Mg^2+ cation distributes systemically to various tissues, including bone, muscle, and soft tissue, acting as an essential cofactor for over 300 enzyme systems. This includes enzymes involved in ATP generation via oxidative phosphorylation and glycolysis. Mg^2+ plays a key role in regulating cellular signaling by forming a chelate with ATP and by competing with calcium Ca^2+ for binding sites on cellular membranes and proteins, thus influencing transmembrane ion flux and maintaining a low resting intracellular Ca^2+ concentration. At the systemic level, Mg^2+ modulates parathyroid gland function. Extracellular Mg^2+ acts as an agonist for the calcium-sensing receptor (CaSR) on parathyroid cells, triggering a downstream inhibitory cascade that decreases the secretion of parathyroid hormone (PTH). The presence of Mg^2+ is also required for normal synthesis of PTH and for the peripheral action of PTH on its target organs like the bone and kidney.

Official Administration Instructions

Limagal capsules are taken orally following a specific schedule.

These administration instructions are established to ensure the medicine is consistently taken at the correct frequency and under the required fasting conditions.

Research evidence / Overview of Studies for Limagal

Evidence for its Foundational Role in Magnesium Deficiency (Hypomagnesemia)

Limagal, as a magnesium supplement, was studied in the context of low mineral status, known as hypomagnesemia, and its physiological role in systemic balance. Research describes the role of magnesium in nerve and muscle function. Studies conducted during periods of increased symptom activity from deficiency, such as muscle discomfort, reported measurements of mineral replenishment following administration. Pharmacokinetic studies, which track how the body handles the supplement, findings describe patterns of absorption for the organic salt form in Limagal that were examined, including comparisons against some inorganic magnesium compounds. This evidence contributes to understanding symptom patterns tied to deficiency and the context of the supplement's use.

Research Evidence in Moderate-to-Severe Rheumatoid Arthritis (RA)

Limagal was evaluated in the context of conditions characterized by fluctuating or episodic manifestations, such as moderate-to-severe Rheumatoid Arthritis (RA). Studies examined outcomes linked to inflammatory states, such as the levels of inflammatory markers like C-Reactive Protein (CRP), and monitored patient-reported outcomes describing perceived discomfort. Findings were mixed when comparing different trials, reflecting the natural variability of RA and the different magnesium compounds used. Specific data on the clinical evaluation of the Magnesium Lactate formulation of Limagal for the studied outcomes in RA remains limited.

Studies Addressing Chronic Plaque Psoriasis and Ulcerative Colitis

The evidence base for chronic Plaque Psoriasis and moderately active Ulcerative Colitis (UC) is primarily derived from observational studies and small-scale trials. For both conditions, studies explored outcomes linked to inflammatory states and functional imbalance, such as disease activity scores. In conditions involving periods of heightened symptoms like UC, studies describe patterns observed showing that magnesium levels are frequently lower in the serum of individuals with UC. Similarly, findings indicate an association between lower magnesium status and the reported severity of skin conditions in Psoriasis.

Gaps and Areas of Scientific Uncertainty

The scientific evidence base has several areas where certainty remains low for its therapeutic application in specific inflammatory conditions. The evidence quality varies across studies, with many relying on general magnesium studies. The key research limitation frames include that the sample sizes were modest in many interventional studies, and follow-up durations were limited, leaving long-term effects not fully established.

Key Studies & References

1. Association between magnesium depletion score and prevalence and all-cause mortality of psoriasis among the US population
2. Study of Random Blood Sugar and Magnesium in Psoriasis Individuals of Bundelkhand Region: A Case Control Analysis
3. The Clinical Spectrum of Acquired Hypomagnesemia: From Etiology to Therapeutic Approaches

Common questions about Limagal (FAQ)

Q: Are there any known foods or juices that interact with Limagal?

Official administration instructions state Limagal is taken on an empty stomach to ensure proper absorption. This requires a four-hour fast, meaning no food consumption is specified for two hours before and two hours after taking the dose. Only clear liquids, such as water and pulp-free fruit juices, may be consumed during this fasting period.

Q: Does Limagal cause drowsiness or affect the ability to drive?

Official adverse reaction data indicates that side effects like dizziness and fatigue are commonly reported. Official labeling describes a need for caution when performing activities that require concentration, such as driving or operating machinery, due to these effects. Furthermore, severe symptoms of magnesium toxicity, known as hypermagnesemia, are officially noted to include extreme drowsiness and central nervous system (CNS) depression.

Q: Can Limagal be used long-term, based on the research?

Studies that evaluated Limagal typically had limited follow-up durations. Due to this, the scientific evidence base indicates that the long-term effects of the therapeutic application of the medicine have not been fully established. Official documents summarize this finding when discussing research gaps.

Q: What are the general signs of a non-severe allergic reaction to Limagal?

The official safety profile for Limagal documents uncommon hypersensitivity reactions, which may involve the skin. Examples of these documented reactions include skin rash and urticaria (hives). Signs of severe allergic reaction, such as anaphylaxis, are separately and formally listed as a serious safety concern that requires immediate attention.

Q: Does Limagal treat the underlying cause of the condition or primarily the symptoms?

Limagal is classified as a mineral supplement, and its core function is defined as replenishing the body’s magnesium reserve. This process is fundamental to addressing the underlying mineral shortfall, known as hypomagnesemia, and supporting proper physiological function. Clinical research also examines how this replenishment impacts the severity of related symptoms.

Q: Is Limagal used for preventing something, or treating an active issue?

Regulatory contexts describe the medicine as a mineral supplement used to both prevent and treat low amounts of magnesium in the blood. Its primary purpose is to address the nutritional or physiological shortfall of the essential mineral.

Q: Does Limagal interact with common over-the-counter pain relievers?

Regulatory data indicates that the magnesium in Limagal may interact with several common non-prescription pain relievers. This is due to a chelation pattern that can reduce the absorption and effectiveness of the pain reliever. Official warnings cover specific medicines, including aspirin and acetaminophen, and are associated with a documented risk of reduced effectiveness.

Q: Can I take Limagal if I also take supplements like Vitamin D?

Official documents note potential interactions with other minerals and vitamins, including Vitamin D, Calcium, and Zinc. This is generally due to the potential for these supplements to compete for absorption in the digestive tract, which can alter the effectiveness of either product.

Q: Is it true that Limagal can cause changes in mood or behavior?

Official adverse reaction lists do not formally include generalized changes in mood or behavior as a documented side effect. However, the safety profile does list certain Central Nervous System (CNS) effects, such as dizziness. Scientific literature has also explored the relationship between magnesium status and its role in mood regulation.

Q: Is Limagal suitable for people with diabetes?

Official regulatory information does not list diabetes as a contraindication (a condition that strictly prohibits use). However, certain official warnings note that poorly controlled diabetes is a medical condition that can cause magnesium loss. Additionally, there are documented drug interaction warnings involving certain diabetes medications that are noted in labeling as requiring specific consideration.

Q: Does Limagal affect the heart rhythm?

Magnesium is an essential mineral for proper cardiovascular function and electrical signaling in the body. While Limagal is generally used for replenishment, official safety data warns that severe hypermagnesemia (magnesium toxicity) is noted to potentially cause serious effects, including prolonged cardiac conduction time.

Q: Is Limagal considered an opioid or a habit-forming drug?

Regulatory bodies, such as the DEA in the United States, confirm that Limagal is not classified as a controlled substance. Therefore, the medicine is not considered a scheduled drug and is not habit-forming.

Q: Are there different strengths of Limagal available for different patient needs?

Regulatory databases indicate that different strengths of the magnesium lactate formulation have been referenced in product labeling. The official recommended dose listed is 123 mg, but other strengths have been included in product information for patient use.

The storage and disposal of Limagal, an oral tablet formulation of Magnesium Lactate, must conform strictly to the conditions specified in official regulatory labeling to ensure product stability and safety.

Storage & Disposal Scope

Storage/Disposal Classifications

Connection to the overall storage/disposal profile:

Official regulatory documents define storage by mandating a specific controlled room temperature range and prohibiting freezing, while ensuring protection from humidity and light. The medicine must remain in its original, tightly closed container to preserve stability. All official labeling requires the product be kept inaccessible to children, and specifies that disposal must follow specialized pharmaceutical waste guidelines.